GlassScriptPhysician profile
Jane M Temple
NPI 1629463799
$937.60
in general payments reported to CMS, 2019-2025
10 companies · $284 in 2025
The $284 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $91.39 · 2022: $99.99 · 2023: $305 · 2024: $157 · 2025: $284.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547 · Education: $199.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $547.23 |
| Education | $198.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $189.80 | 2021-2023 | Pemazyre |
| Astrazeneca Pharmaceuticals LP | $122.47 | 2024 | Imfinzi |
| Pharmaessentia USA Corporation | $107.92 | 2023 | Besremi |
| Ipsen Biopharmaceuticals, INC | $99.99 | 2025 | |
| Aveo Pharmaceuticals, INC. | $99.99 | 2022 | |
| Gilead Sciences, INC. | $99.00 | 2023 | Trodelvy |
| Astellas Pharma US INC | $90.73 | 2025 | Vyloy |
| Abbvie INC. | $88.98 | 2024-2025 | |
| Tempus Ai, INC | $19.53 | 2025 | Xt Cdx |
| Alcresta Therapeutics, INC. | $19.19 | 2025 | Relizorb |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Temple listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.